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Increasing fatal AA amyloidosis in hunting falcons and how to
identify the risk: a report from the United Arab Emirates
Abstract
In hunting falcons, a fatal syndrome of wasting, weight loss, green mutes and, finally, sudden death of
emaciated birds has been observed in the United Arab Emirates (UAE). Histological examination using
Congo red has revealed amyloid in most organs, in particular in the liver, spleen, kidney, and adrenal
glands. Moreover, a retrospective study revealed amyloidosis in 100 cases among a total of 623
necropsied falcons between August 1995 and March 2004 in Dubai/UAE (16%; varying from 8 to 30%
in different raptor bird species). The amyloid was immunohistochemically classified as amyloid A
(AA), which was confirmed by Western blot analysis and N-terminal amino acid sequence analysis,
suggesting it to be secondary to a chronic inflammatory process. Retrospective analysis has indicated a
significantly increased prevalence of bumble foot and visceral gout among falcons with amyloidosis. In
addition, a significant increase of amyloidosis from 5.6% of necropsied falcons with amyloidosis in
1995 to 40.0% in 2004 has been noticed. Finally, a semi-quantitative serum test for falcon serum
amyloid A (f-SAA) has been developed. Among 38 falcons with fatal AA amyloidosis, f-SAA was
increased pathologically in 36, whereas f-SAA was elevated in only one of 15 apparently disease-free
falcons (p < 0.001). This significant result indicates that a normal f-SAA will indicate a minimal or even
absent risk of succumbing to AA amyloidosis.
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Abstract
In hunting falcons, a fatal syndrome of wasting, weight loss, green mutes and, finally, sudden death of emaciated birds has
been observed in the United Arab Emirates (UAE). Histological examination using Congo red has revealed amyloid in most
organs, in particular in the liver, spleen, kidney, and adrenal glands. Moreover, a retrospective study revealed amyloidosis in
100 cases among a total of 623 necropsied falcons between August 1995 and March 2004 in Dubai/UAE (16%; varying from
8 to 30% in different raptor bird species). The amyloid was immunohistochemically classified as amyloid A (AA), which was
confirmed by Western blot analysis and N-terminal amino acid sequence analysis, suggesting it to be secondary to a chronic
inflammatory process. Retrospective analysis has indicated a significantly increased prevalence of bumble foot and visceral
gout among falcons with amyloidosis. In addition, a significant increase of amyloidosis from 5.6% of necropsied falcons with
amyloidosis in 1995 to 40.0% in 2004 has been noticed.
Finally, a semi-quantitative serum test for falcon serum amyloid A (f-SAA) has been developed. Among 38 falcons with
fatal AA amyloidosis, f-SAA was increased pathologically in 36, whereas f-SAA was elevated in only one of 15 apparently
disease-free falcons (p5 0.001). This significant result indicates that a normal f-SAA will indicate a minimal or even absent
risk of succumbing to AA amyloidosis.
Introduction
Falconry has an important tradition in the Arabic
world. Frederick II of Hohenstaufen has canonized it
in Europe in his famous masterwork [1], which sum-
marizes the state of falconry in the 13th century.
Today, half of the falconers alone are operative in the
Middle East. The importance of falconry is evident
in particular from the fact that Islam itself permits
falcons for hunting.
In several veterinary clinics of the United
Arab Emirates (see Acknowledgement section),
an increasing number of cases involving a fatal
wasting disease in falcons has been noticed
during the last years and its cause has initiated
some concerns. Examinations have revealed amy-
loid A (AA) amyloidosis to be the cause of this
disease.
Systemic AA amyloidosis has been reported in
most mammals, including humans, and in some
birds. In general, this disease is the result of long-
lasting inflammations in humans [2–5] and in animal
species [6–10].
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AA amyloidosis (as other classes of amyloid) is
diagnosed on tissue sections through the recognition
of extracellular protein deposits, after using the
Congo red (CR) staining method [11]. Although its
pathogenesis is not completely understood, reducing
the inflammatory load can arrest and even prevent its
progression in humans [3,4,12,13].
In mammals, AA amyloidosis has been reported in
canines [14,15], felines [16–18], bovines [19,20],
ovines [21,22], porcines [23], equines [24], lago-
morphs [25], and other species [6,26], besides other
amyloid types [10].
In birds, only the AA type of amyloid has been
reported and it was found to be chemically homo-
logous to mammalian AA. Avian AA protein has
been sequenced in ducks [27–29], geese [30], and
chickens [31]. In addition, avian AA amyloidosis was
also diagnosed immunohistochemically in a variety
of bird families [32,33], although an earlier report on
amyloidosis in the falconiformes did not include its
classification [34].
In this report, we have analyzed the chemical
nature of amyloid in falcons and identified its cause
as driven by inflammation. In addition, evidence for
a genetically transmitted factor has been presented
and infectious agents causing falcon AA amyloidosis
have been identified. Finally, for early diagnosis and
therapeutic considerations, a serum test is reported,
which will become of value in identifying the risk for
falcons of succumbing to the fatal AA amyloidosis.
Materials and methods
Falcons and tissue sections
Necropsies of 623 falcons were conducted at the
Central Veterinary Research Laboratory (CVRL) in
Dubai/UAE between August 1995 and March 2004.
The falcons were brought to the CVRL from other
Arabic institutions which are mentioned in the
Acknowledgement section.
A review of the charts of all 623 falcons was made
concerning their inflammatory conditions and con-
cerning their microbial infections by laboratory
standard methods.
Organs of all necropsied falcons were fixed in 10%
formalin (buffered 4% formaldehyde) and embedded
in paraffin. For histopathological examination, 4–6
mm tissue sections were prepared.
Diagnosis of amyloid
All sections were stained with hematoxylin/eosin
(HE) [35] and with CR [11]. Amyloid was examined
microscopically in bright light for the presence of
amorphous, eosinophilic, extracellular material, as
revealed by HE staining, for its affinity for CR, for its
green birefringence (GB) in polarized light [11] and
for its orange-red Congo red fluorescence (CRF) in
blue excitation [36].
Such tissue samples from 100 falcons with amyloid
(out of 623 necropsies) were examined as liver,
kidney, adrenal glands, spleen, intestine and other or-
gans. In addition, 43 liver biopsies of falcons without
amyloidosis were also available, which were processed
by the same procedure and examined as controls.
Electron microscopy was performed on formalin-
fixed and paraffin-embedded hepatic amyloid con-
taining tissue of a Gyr falcon re-embedded in Araldite
by standard techniques. Ultrathin sections (50 nm)
were placed on Pilioform-covered nickel grids, mesh
150, contrasted with uranyl acetate and lead citrate,
and photographed with a Zeiss electron microscope.
Classification of the falcon amyloid
Classification of the falcon amyloid was performed
immunohistochemically on paraffin sections using
the peroxidase-anti-peroxidase (PAP) system of
Sternberger with H2O2 as a substrate and ami-
noethylcarbazole as a chromogen as described
[36–38]. The antibodies applied were murine mono-
clonal mc1 (also available from Dako) and mc29
(known to cross-react with most species) directed
against human AA [37] and three polyclonal rabbit
antibodies directed against human and bovine AA
[32], and against murine AA [7]. Included was also a
rabbit anti-human ALl (HAR) antibody known to
cross-react with ALl amyloid of humans, canines,
felines, and equines [39–41].
Molecular size of falcon-AA and its protein precursor
falcon serum amyloid A protein
To identify the molecular size of the falcon AA (f-AA)-
protein and the falcon serum amyloid A protein (f-
SAA), serum samples of falcons with AA amyloidosis
and the f-AA extracted from a formalin-fixed liver [42]
were separated using sodium dodecyl sulfate-polyacry-
lamidegel electrophoresis (SDS-PAGE)at12.5%[43].
Controls were serum samples of falcons, which were
apparently disease-free. Bromphenol blue as tracking
dye and marker proteins of known size were run in
parallel. The position of the size markers was used to
create a calibration curve by which the molecular
weights of the protein bands were estimated.
The resulting gels were either stained with
Coomassie blue or examined by Western blotting.
After electrotransfer onto nitrocellulose (NC, B 86;
Schleicher & Schu¨ll, Dassel/Germany), immunode-
tection followed [44].
Partial amino acid sequence of the f-amyloid protein
AA protein was extracted from a formalin-fixed,
paraffin-embedded falcon hepatic tissue loaded with
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amyloid, dialyzed against water and lyophilized as
published [42].
For N-terminal amino acid sequence analysis, the
extracted proteins were separated by SDS-PAGE
(15%) and then electro-transferred onto a polyvi-
nylidene difluoride membrane [45]. The blotted
protein bands were stained with Coomassie blue for
1 min. After destaining, the bands were excised and
sequenced on a Procise 492 pulsed liquid phase seq-
uencer (Applied Biosystems, Foster City, CA). For
analyzing internal peptides, in situ digestion of the
proteins was performed by the method of Patterson
[46] using endoproteinase LysC. Proteolytic frag-
ments were separated by high-performance liquid
chromatography (Hewlett Packard 1100) on a Puro-
sphere RP18 reversed-phase column (Merck, Darm-
stadt, Germany) (1 mm by 150 mm). Solvent A was
0.1% trifluoroacetic acid, and solvent B was 0.08%
trifluoroacetic acid in acetonitrile. The gradient was
0–60% solvent B over a period of 90 min at a flow
rate of 60 ml/min. The peptides were sequenced [47]
on a Procise 492 sequencer according to the
manufacturer’s instructions.
For sequence queries, Basic Local Alignment
Search Tool Protein Query (BLASTP) [48] was
applied searching SwissProt databases.
Detection and quantification of the falcon serum amyloid
A protein
Blood samples. Blood serum was available from all
40 falcons in which diagnosis of amyloidosis had
been made on bioptic and autoptic samples. Blood
samples were taken from the vena ulnaris with a 25 G
needle (0.50 mm6 16 mm) under Isoflurane (Iso-
Flu Abbott, Laboratories, Queensborough, UK)
anesthesia. Additional sera were available from 43
apparently disease-free falcons. The blood was
allowed to clot at room temperature for 2 h and the
clot was sedimented at 800g for 10 min. The serum
was frozen immediately and stored at7208C.
Micro-ELISA
Dotblot-Micro-ELISA for falcon serum amyloid A
protein. The f-SAA, was semi-quantitated using
the dot immunoassay [49]. Control antigen was
pure human AA, which was prepared after water
extraction of native amyloid fibrils from frozen tissue
as published [50]. The pure fibril monomeric AA
(KIR) was isolated by gel filtration on Sephadex G-
100 in 6 M guanidine-HCl according to Ref. [3]
yielding a single band of 8.6 kDa as proven by SDS-
PAGE electrophoresis [43]. The N-terminal amino
acid sequence of this control protein showed the
known sequence of AA according to Ref. [2]. This
pure AA (KIR) protein at 100 mg/ml, under 0.03 M
barbital puffer, pH 8.6, served as a standard.
The standard AA protein was run in parallel in a
series of known protein concentrations in the same
assay. The blotted proteins were immunochemically
identified using the PAP technique as mentioned
above. The f-SAA concentration could be estimated
semi-quantitatively from the intensity of staining,
which was compared by inspection with that of the
standard AA protein of known amounts.
Statistical analysis
The statistical analysis was carried out using Micro-
soft Excel and Stratgraphic plus Version 5. Chi-
Square ‘Goodness of Fit’ test was used to assess the
independence of amyloid occurrence of falcon
species and diagnosed disease [51]. Others were
carried out according to Ref. [52] with comparable
results (by courtesy of Prof. R. Schuster).
Results
Novel falcon disease
The disease commenced with an uncharacteristic
syndrome including more slow reactions and
the appearance of a possible type of depression
(Figure 1), followed by clinical signs presenting as a
Figure 1. Lethargic and depressed appearance of a gyr falcon
affected with AA amyloidosis (2-year-old female, diagnosis
through liver biopsy).
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reduction of appetite, fatigue, and unwillingness to
fly. Later, these signs worsened, resulting ultimately
in a severe apathy extending to a lack of flying,
complete loss of appetite, followed by significant
weight loss, and green mutes, a syndrome which was
often followed by sudden death associated with
severe emaciation.
Necropsy and the diagnosis of amyloid
Post-mortem examination revealed significant en-
largement of involved organs with discoloration and
a waxy, easily breakable consistency which was a
major characteristic of many falcons with amyloido-
sis, macroscopically (Figure 2).
Amyloid was detected histologically in paraffin
sections after CR staining in 100 (16.0%) falcons out
of a total of 623 necropsies. As illustrated in Figure
3a, a pinkish red coloration marks the amyloid after
CR-staining, whereas the GB in polarized light
identifies amyloid (Figure 3b). In Figure 3c, the
highly sensitive CRF is shown that identifies the
entire amyloid mass at the same time.
In 86 examined livers, liver being the main target
organ, massive amyloid was recorded out of the 100
falcons. In the remaining 14 falcons without data on
hepatic histology in the charts, amyloid was diag-
nosed by way of such other organs as kidneys, spleen,
adrenals, pancreas, and gut. The amyloid was mainly
found as an amorphous, eosinophilic, extracellular
material in the capillary space of Disse, resulting in
atrophy of the hepatocytic sheets in some severe
cases. Renal amyloid was detected in the cortical and
peritubular interstitium (Figure 3f), whereas the
glomeruli remained largely amyloid-free.
Similar to AA amyloid deposits of many other
species, the falcon AA amyloid is a systemic,
predominantly vascular amyloidosis starting at the
subendothelial site. In addition, a chronic inflamma-
tion was indicated in many organs by slight to
moderate infiltration of some perivascular sheets
with mononuclear cells. The nervous system (brain,
cerebellum, medulla oblongata, spinal cord) was not
affected.
Electron microscopy revealed characteristic amy-
loid fibrils of *10 nm diameter. The fibrils were
straight, unbranched, and of undetermined length.
They were deposited as dense bundles of more or
less parallel fibrils (Figure 4). At other places they
were deposited more irregularly (not shown).
Classification of the falcon amyloid
This chemical amyloid class was then identified
immunohistochemically in liver, spleen, and kidney
of four falcons as being of the AA type. In three livers
without amyloidosis no reaction was seen. An
example is illustrated in Figure 3. The main immu-
nohistochemical reaction was provided by the mono-
clonal AA antibody mc29 which shows strong staining
of hepatic (Figure 3e) and renal (Figure 3f) amyloid,
whereas monoclonal AA (mc1)-antibody was unreac-
tive (negative control, not shown). In addition,
polyclonal AA antibodies against mammals (cow,
mouse, and humans) did not cross-react with falcon
AA amyloid. Moreover, the anti-human ALl (HAR)
also failed to react with falcon amyloid as well
(Figure 3d) indicating strongly that falcon amyloid is
not of the ALl amyloid class. Finally, this falcon
amyloid was shown to be permanganate sensitive [53].
Molecular size of falcon serum amyloid A protein and
falcon-AA
To identify the molecular size of f-SAA, each of some
falcon sera were separated by SDS-PAGE and the
bands were examined for AA antigenic reactivity
using Western blotting with mc29. The Coomassie
blue-stained size-separated bands (Figure 5, left)
showed a difference in the low-molecular weight
Figure 2. Necropsy of a falcon with amyloidosis. Diagnosis of
amyloid through histological evaluation (see Figure 3). Massive
hepatomegaly with typical greenish–brownish discoloration of the
liver (bottom arrows). Fibrinous perihepatitis and pericarditis. The
heart is of normal size (top arrow). In this falcon, a Pseudomonas
aeruginosa infection and chronic aspergillosis (left arrow) was
diagnosed.
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Figure 3. Diagnosis and classification of falcon amyloid on paraffin sections (Counterstain hematoxylin; magnification 1606). (a–c)
Diagnosing amyloid using the Congo red procedure. (a) Liver infiltrated with masses of amorphous, eosinophilic, extracellular material
along the capillary space of Disse. Amyloid is indicated by the pinkish coloration. (b) The same section as in a. in polarized light. The green
birefringence identifies amyloid. However, due to the ‘polarization shadow’ [36], only a fraction of the amyloid mass reveals this
pathognomonic trait at a defined position of the polarization filters. Different parts of the amyloid mass will show this trait after turning the
slide table. (c) The same section as in (a) and (b) in fluorescent light. Different from the situation in (b), the whole amyloid mass is
illuminated at the same time. The amyloid appears orange-red using excitation in blue light with a barrier filter, that permits the green to red
light to pass; for FITC (fluorescein isothiocyanate) [36]. (d–f) Immunohistochemical identification of falcon amyloid as AA type. (d) Liver
amyloid immunohistochemically negative control reaction using anti-ALl (HAR) as primary antibody. (e) Liver, immunohistochemically
stained with anti-AA (mc29) reveals a strong reaction of all amyloid deposits. Brown-reddish coloration marks the amyloid. (f) Kidney,
immunohistochemical staining of peritubular and interstitial amyloid at moderate extent. (Note the characteristic intravasal avian nucleated
erythrocytes, which are also seen in a-e).
126 M. R. Hampel et al.
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region pointing to a faint band in the acute phase
serum (see arrow in lane 2) in contrast to the normal
falcon serum (lane 1). The following immunochem-
ical analysis of this band revealed a single very strong
reaction with mc29 in full acute phase serum which
identified an AA-antigenic protein of 11.0 kDa which
represents f-SAA (Figure 5 right, lane 2, see arrow).
In addition, a faint band of the same size is also seen
in normal falcon serum (Figure 5, right, lane 1) which
represents the normal f-SAA. The molecular weight
of the f-AA protein was determined likewise. Major
bands of 8, 16, and 24 kDa size (with a reduction in
concentration, in that order) were labelled strongly
with mc29 immunochemically (not shown).
N-terminal amino acid sequence
The N-terminal amino acid sequence analysis was
determined from peptides of the 8 kDa moiety
isolated from the f-AA protein as shown in Figure 6.
In addition, the falcon sequence was compared with
the five published sequences that have been deter-
mined from tissue amyloid protein and/or from the
nucleotide sequences of ducks, geese, and chickens
[27–31] and compared with humans [54].
The obtained sequence of 23 amino acids com-
mences at position 1 of the N-terminus of the mature
protein as compared with the other sequences of
other birds. The N-terminal heptapeptide has no
homology with the sequence of AA amyloid proteins
of other avian and mammalian species, including that
of humans [21,42,54]. In addition, a Basic Local
Alignment Search Tool (BLAST) search did not
reveal any hint to its significance. By the way, the
subsequent sequence at position 8 and 9 is identical
with that of the other birds, but not with that of
humans and other mammals [21]. However, pheny-
lalanine at position 10 is identical in most if not all AA
proteins [21,42,54], and from this position on
homology is shown till the end at position 23 of the
falcon peptide.
The 8–23 segment represents a relatively variable
region of avian AA when compared with the other
more complete sequences of 109 amino acids of
ducks and geese [27–30], of 106 amino acids in a
duck [28] and 57 residues in a chicken AA protein
(31). So, within the sequence from position 24 to the
C-terminus, only one single amino acid exchange
occurs at position 70 between ducks and geese
(marked in red) (Figure 6). Similarly invariable is the
leader sequence between ducks and geese, with only
one exchange at position -8 (A-S) (marked in red)
due to one nucleotide exchange. The number of
identical amino acids of the falcon sequence 8–23 to
the homologous sequence of ducks, geese and
chickens are numbered 13, 12 and 10, respectively.
In addition, the three amino acid exchanges
identified as compared with ducks are at position
12 (falcon-duck: W-L), 15 (V-A), and 22 (Y-L), and
are caused by single nucleotide exchanges in the first
two, and two exchanges in the latter amino acid
exchange. Although these three exchanges are con-
servative, a slight increase of hydrophobicity in the
falcon sequence as compared with that in the duck
could be inferred.
Finally, the amino acids marked in green in the
human AA protein indicate the three positions in
Figure 4. Electron microscopy of hepatic falcon amyloid fibrils are
seen arranged in bundles (longitudinal and perpendicular view;
diameter of the amyloid fibrils approximately 10 nm).
Figure 5. Identification of f-SAA using size separation followed by
Western blotting. Left: SDS-PAGE separation of normal falcon
serum without (lane 1) and serum of another falcon with an acute
phase reaction and amyloidosis (lane 2). m represents molecular
weight markers. Coomassie blue staining of proteins. Arrow points
to a low-molecular weight protein in the region of f-SAA (note the
difference between lane 1 and 2 with an increase of the
concentration of a protein at the 11.0 kDa position). Right:
SDS-PAGE separation as performed in Left followed by Western
blotting using anti-AA (mc29). In normal falcon serum (lane 1) at
the position of 11.0 kDa a trace of f-SAA can be identified whereas
at the same position in an falcon acute phase serum a very
intensive reaction can be seen indicating a significant increase of
SAA at the same position of 11.0 kDa in lane 2 (see arrow). As
molecular weight markers vanish during Western blotting, the
exact position of the marker ladder has been copied from the
NC-membrane after electrotransfer before Western blotting.
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which the human differs from the avian constant
positions within the 23-mer sequenced as shown in
Figure 6.
Susceptibility of the different falcon species to succumb to
AA amyloidosis
The data on the prevalence of amyloidosis among the
different falcon species are shown in Table I as
compiled from the charts. It is clear from these data
that the pure gyr falcons are the most susceptible as
40 (30.0%) out of the 132 examined gyr falcons
succumbed to amyloidosis, whereas only 18 of the
142 peregrine falcons (12.7%) were affected. The
most resistant were the saker falcons with only 8.7%
diseased by amyloidosis. Interestingly, the gyr
hybrids were remarkably protected (16.7%), as
compared with the pure gyr falcons. Finally, falcons
whose species were not recorded (because they were
possibly the smallest and the least conspicuous ones)
belong to the most resistant class.
Statistical analysis revealed that only the preva-
lence of amyloidosis in the gyr falcon related to this
species was highly significant (p5 0.001). When the
gyr falcons were removed before a second analysis,
the remaining cohort of falcon species (peregrine,
saker, gyr hybrids and unknown falcon species) did
not show a statistically significant difference to the
occurrence of amyloidosis demonstrated in the
remaining species (p¼ 0.1507).
Inflammatory load in falcons with and without
amyloidosis
To find out which of the common inflammatory
states, such as chronic, visceral gout, aspergillosis or
the numerous infectious agents, are prevalent in
falcons with amyloidosis, as compared with those
without any chronic inflammation, all available data
from the 623 examined falcons were compiled and
statistically analyzed as shown in Table II. Although
tuberculosis and poxvirus had a tendency to act as an
agent, statistical analysis did not support this
impression in this series of falcons. By contrast, it
is clear from the statistical data that only two
conditions are found to be elevated significantly in
falcons with amyloidosis – bumble foot and chronic
visceral gout. Which inflammatory events can defend
falcons from the chronicity of inflammations (as
perhaps in the different not identified falcon species)
needs to be further examined.
Recent, notably increased prevalence of amyloidosis in
falcons
The incidence of amyloidosis among the necropsied
100 falcons is shown in Figure 7. These data derived
from the charts illustrate a notably steep increase in
the prevalence of amyloidosis during the most recent
time period spanning the years from 1996 to 2004.
The detailed contribution of this increase of the
individual falcon species has not been examined yet.
However, the overall prevalence of falcon amyloido-
sis suggests that the gyr falcons contributed most as
compared with the other falcon species (Table I).
Figure 6. N-terminal amino acid sequence of falcon AA amyloid. Comparison with AA proteins reported from other birds and humans.
Blue: identity of falcon AA protein with duck, goose, chicken and humans. Red: single amino acid exchanges in the signal peptide and at
position-8 and at position 70 of the mature protein in duck and goose. Green: Three human amino acids different from falcon, chicken,
duck, and goose.
Table I. Prevalence of amyloidosis within the different falcon
species.
Falcon species
All autopsies
Autopsies with
amyloidosis
Number % Number %
Gyr 132 21.2 40 30.3
Gyr hybrid 150 24.1 25 16.7
Peregrine 142 22.8 18 12.7
Saker 80 12.8 7 8.7
Unknown/other 119 19.1 10 8.4
Total 623 100.0 100 14.9
128 M. R. Hampel et al.
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Quantification of falcon serum amyloid A protein
The first results of the dot immunoassay developed
with the monoclonal AA antibody (mc29) revealed a
sensitivity of *2 mg f-SAA/ml based on the highly
and chemically characterized human AA (KIR) pro-
tein as a standard (determined on the intensity of the
staining). Values above 20 mg/ml were considered
pathologic, since the f-SAA values were below 10 mg/
ml in most healthy falcons. Comparing the sera of
falcons with and without amyloidosis, the following
data were found: The f-SAA values of the 38 falcons
with AA amyloidosis were pathologically elevated in
36. By contrast, in the 15 apparently disease-free fal-
cons, only one had elevated f-SAA values. This dif-
ference is statistically highly significant (p5 0.001).
A more detailed account of this part is in progress.
Discussion
This report establishes that a fatal disease in hunting
falcons, which is new in Dubai, is based on the
deposition of AA amyloid in various organs. The
prevalence of systemic AA amyloidosis is a major
cause of death in hunting falcons, because it was
identified in 16% out of 623 necropsies from the
UAE and neighboring states. In addition, this high
prevalence of AA amyloidosis has increased more
than fourfold during the years 1996–2004 (Figure 7),
as taken from the charts.
The chemical nature of the predominant protein in
falcon amyloid was identified immunohistochemi-
cally and established chemically by N-terminal amino
acid sequence analysis. As the size of this AA-protein
of 8 kDa is smaller than that of its serum precursor
(11.0 kDa) as found in humans, limited proteolysis of
f-SAA can be inferred in the pathogenesis of the f-AA
amyloidosis in line with the pathogenesis of AA
amyloidosis in men [3,12,13] and in animals [10,21].
The main target organ of the falcon AA amyloi-
dosis is the liver, which showed in many cases a
characteristic green discoloration caused by bile
stasis (Figure 2). Bile stasis has been described in
inflammations, infections, neoplasia, toxic insults,
and lipoidosis [55]. Now, inflammation with hepatic
amyloidosis can be added to this list. The liver is
followed by the kidneys, spleen, and adrenal glands,
which is similar to the distribution in another bird, the
duck, in which the liver is also reported to be the
predominantly affected organ [27]. As the glomeruli
are not generally the preferred target for amyloid in
falcons, it can be assumed that the majority of falcons
die from liver failure. This is in contrast to AA-
amyloidosis in humans (and other mammals),
which leads to fatal renal failure in the majority of
patients [3,13]. The major target of amyloid distribu-
tion varies in different species, as shown in Table III.
The amyloid distribution in falcons (and possibly
in other birds) may indicate that the liver is most
susceptible and/or that the causative agent inducing
this disease could reside in the liver earlier and/or in a
higher concentration than in other organs.
Table II. Prevalence of inflammatory events in 523 falcons without
amyloidosis (I) as compared to 100 falcons with amyloidosis (II)
including statistical evaluation.
I II Significance
a
for amyloid,
Diseases Number % Number % p-value
Aspergillosis 74 14.1 19 19 0.1724
Bumblefoot 0 0 23 23 50.001
Chlamydiosis 22 4.2 0 0
Clostridiosis 99 18.9 0 0
Gout 38 7.3 26 26 0.0074
Herpes virus 43 8.2 0 0
Intoxication 5 1 0 0
Paramyxovirus 36 6.9 0 0
Pasteurellosis 2 0.4 0 0
Parasites 38 7.3 9 9 40.3049
Pneumonia 3 0.6 0 0
Poxvirus 6 1.1 6 6 0.1203
Salmonellosis 34 6.5 0 0
Tuberculosis 10 1.9 8 8 0.1447
Others 113 21.6 9 9 50.001
Total 523 100 100 100
aValues given by fat italic indicates significance.
Figure 7. Increasing prevalence of AA amyloidosis in falcons
during 1996–2004.
Table III. Main organ involvement of AA amyloid in different
animals.
Animal Organ Reference
Cow Kidney 19
Cheetah Kidney 56
Hamster Kidney 57
Horse Digestive tract 58
Mink Spleen 59
Duck Liver 27
Dog Joint 15
Chicken Joint 31
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Different susceptibility for acquiring AA amyloi-
dosis has been observed among the different falcon
species, with the highest found in gyr falcons. This
difference was significant when compared with the
non-gyr falcons. However, the prevalence of AA
amyloidosis among the non-gyr falcon species was
not significant, including that found in the gyr
hybrids.
The latter finding of a reduction of the prevalence
of amyloidosis in gyr hybrids points to a decisive
resistance factor, which is being genetically trans-
mitted by cross-breading. The nature and the action
of this factor needs to be delineated. Hereditary
transmission has been reported in cats [16] and dogs
[60]. Autosomal dominant (and, in some syndromes,
also recessive) transmission of amyloidosis has been
reported in humans in several different hereditary
amyloid classes [61,62], including AA amyloidosis,
in which different genetic defects in proteins along
the fever cascade have been described [63,64].
Whether the cause of the falcon AA amyloidosis is
based on a single mechanism and whether it follows
some of the aforementioned patterns needs to be
explored.
There may be contributions to amyloidosis from
the fact that falcons are bred by in vitro fertilization,
which may have compromised the immune system
through the reduction of variability. Another possi-
bility could be an altered structure of the f-SAA
protein resulting in an increase of amyloidogenicity.
One can also think of a genetic predisposition with the
obviously higher response to stress in gyr falcons,
which may also compromise immunity and thereby
ensue in an increased susceptibility to infectious
agents. A further possibility is contamination
and ingestion of amyloid through a prion mechanism,
as has been shown in several experimental systems
[65]. It is worth mentioning that the French dish foie
gras prepared from the amyloid-loaded liver of the
Pecking duck contains AA fibrils that can accelerate
the development of AA amyloidosis after ingestion
through a prion-like mechanism in mice [66].
The cause of the AA amyloidosis in falcons is
driven by long-standing inflammations with recur-
rent acute exacerbations as known from humans and
animals [2,3,4,10,13]. Accordingly, the charts of the
falcons revealed inflammations of various kinds
(Table II). However, a significant increase of AA
amyloidosis was detected only in bumble foot and
visceral gout. Bumble foot in falcons is known to be
caused by bacterial infections of foot paths due to
permanent sitting. A similar syndrome with amyloi-
dosis has been reported in puppies [67]. By contrast,
tuberculosis, aspergillosis and poxvirus, although
more prevalent in falcons with amyloidosis, were
not statistically significant in this series – probably
due to the low numbers of falcons examined. As
bumble foot and visceral gout account for only a
fraction of all amyloid cases, more infectious agents
have to be assumed as suggested by the category
‘others’ in Table II. In this context, the report of
Gierse [68] on inflammatory diseases in a large series
of 5696 examined falcons demonstrates that various
inflammatory agents are identified which may
have also induced AA-amyloidosis in our series of
falcons.
Various inflammations, tissue damages or neopla-
sias in humans and animals [3,13] result in a steep
increase in the concentration of serum amyloid
A protein (SAA), a 12.5 kDa serum protein that
can lead in sustained inflammation to AA amy-
loidosis when during degradation of SAA to a
8.5 kDa N-terminal hydrophobic fragment of SAA
is transformed and deposited as AA amyloid in
glycosamine-glycan-rich tissue structures [69]. SAA
is monokine-induced in the liver and in several
other extrahepatic tissues [70,71]. A similar mechan-
ism is strongly indicated in falcons by the significant
association of AA amyloidosis with chronic inflam-
mations and the fragmented nature of f-AA (8.0
kDa) which is most probably derived from f-SAA
(11.0 kDa) as reported here.
The risk to succumb to AA amyloidosis has been
estimated through a semiquantitative test of f-SAA.
It has been shown that this test can be used to
distinguish falcons with an acute phase condition in
amyloidotic birds from those without any acute
phase condition. Because an increased f-SAA con-
centration will also be found in non-amyloidogenic
inflammations of short duration, only a long-term f-
SAA increase will pose the falcons at risk, as has been
established in humans [13,72] and animals [10].
Thus, the concentration of SAA could be used to
distinguish falcons with a potential amyloidogenic
inflammation from those falcons which are disease
free. The latter falcons with a normal f-SAA level will
therefore most probably not be as susceptible to
succumb to AA amyloidosis, which is still an illness
that is not yet curable without knowing its cause. In
humans, various therapeutic options have been
reviewed for AA amyloidosis [4,5,13]. In falcons,
the therapy of the specific infections, of gout and
bumble foot and others, will have to be considered
first, monitored by f-SAA determination. In addi-
tion, the possible prevention of AA amyloidosis may
come from the delineation of the possibility of a
susceptibility factor in the gyr-falcon. This assumed
factor was shown here to contribute significantly to
the prevalence of AA amyloidosis in hunting falcons.
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